Tesamorelin/Ipamorelin 10mg/3mg

Tesamorelin/Ipamorelin

Product is sold for prescriber purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

Combining tesamorelin and ipamorelin in rat studies offers a promising avenue for investigating the synergistic effects of growth hormone-releasing agents on various physiological processes. Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has been shown to significantly reduce visceral adipose tissue and improve liver health by decreasing liver fat and preventing fibrosis progression. Ipamorelin, a selective growth hormone secretagogue, has demonstrated efficacy in stimulating growth hormone (GH) release, leading to increased longitudinal bone growth and enhanced bone mineral content in rats.

In a study by Johansen et al., ipamorelin administration in rats resulted in a dose-dependent increase in longitudinal bone growth, attributed to its potent GH-releasing properties. Similarly, research has indicated that ipamorelin can counteract glucocorticoid-induced reductions in bone formation, suggesting its potential in mitigating bone density loss associated with glucocorticoid therapy.

Tesamorelin’s impact on liver health was highlighted in a study where it significantly reduced liver fat and prevented fibrosis progression over a year-long period.  These findings underscore tesamorelin’s potential therapeutic role in managing conditions characterized by excessive visceral fat and liver steatosis.

Combining these peptides in rat models may provide insights into their collective effects on body composition, bone density, and metabolic health. While individual studies have demonstrated the benefits of tesamorelin and ipamorelin separately, research on their combined administration is limited. Further investigations are warranted to elucidate the potential synergistic effects and safety profiles of this combination.

References:

Johansen, P. B., et al. “Ipamorelin, a New Growth-Hormone-Releasing Peptide, Induces Longitudinal Bone Growth in Rats.” Growth Hormone & IGF Research, vol. 9, no. 2, Apr. 1999, pp. 106–113. https://pubmed.ncbi.nlm.nih.gov/10373343/.

Svensson, J., et al. “The GH Secretagogues Ipamorelin and GH-Releasing Peptide-6 Increase Bone Mineral Content in Adult Female Rats.” Journal of Endocrinology, vol. 165, no. 3, June 2000, pp. 569–577. https://joe.bioscientifica.com/view/journals/joe/165/3/569.xml.

Stanley, T. L., et al. “Effects of Tesamorelin on Hepatic Transcriptomic Signatures in HIV-Associated NAFLD.” The Journal of Clinical Endocrinology & Metabolism, vol. 105, no. 10, Oct. 2020, pp. 745–5119. https://pmc.ncbi.nlm.nih.gov/articles/PMC7455119/.